Q2 2020 Esperion Therapeutics Inc Earnings Call
שיחת ועידה Esperion Therapeutics Inc
Esperion Therapeutics Inc Conference call or earnings call will be held on 10/08/2020 via an 800 number (toll-free). During the earnings conference call's session Esperion Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Esperion Therapeutics Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C. ETC-1002, or bempedoic acid, our lead product candidate, is an inhibitor of ATP Citrate Lyase, or ACL, a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors, resulting in increased LDL-C clearance and reduced plasma levels of LDL-C. We held an End-of-Phase 2 meeting with the Food and Drug Administration, or the FDA, in August 2015. We initiated a global Phase 3 long-term safety and tolerability study of bempedoic acid in January 2016, in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. We own the exclusive worldwide rights to bempedoic acid.קרא עוד שיחת ועידה